Drug-Drug Interaction Study With Rifampin

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Alzheimer Disease

Treatments: Drug: Rifampin; Drug: BMS-708163

Study type: Interventional

Funder types: Industry

Identifiers

NCT01002079

CN156-028

Details and patient eligibility

About

The purpose of the study is to determine if the concomitant administration of rifampin with BMS-708163 will affect the Pharmacokinetics of BMS-708163 and to assess safety and tolerability of co-administration BMS-708163 and rifampin

Enrollment: 20 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male and postmenopausal female subjects, 18-55 yrs old inclusive

Exclusion criteria

• Women of childbearing potential
• Tuberculosis

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 3 patient groups

BMS-708163

Experimental group

Treatment:

Drug: BMS-708163

Rifampin

Other group

Treatment:

Drug: Rifampin

Drug: Rifampin

Rifampin + BMS-708163

Experimental group

Treatment:

Drug: BMS-708163

Drug: Rifampin

Drug: Rifampin